Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma.

MLA

Jia, Weiwei, et al. “Advancing Treatment Efficacy: Combined Therapy of Eribulin, Anlotinib, and Camrelizumab in Advanced or Metastatic Retroperitoneal Liposarcoma.” Therapeutic Advances in Medical Oncology, Sept. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1177/17588359241276968.

APA

Jia, W., Wu, J., Zhang, H., Wu, Y., Liu, D., Wang, Z., Wang, X., Li, C., & Hao, C. (2024). Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma. Therapeutic Advances in Medical Oncology, 1–14. https://doi.org/10.1177/17588359241276968

Chicago

Jia, Weiwei, Jianhui Wu, Hongtao Zhang, Yan Wu, Daoning Liu, Zhen Wang, Xiaopeng Wang, Chengpeng Li, and Chunyi Hao. 2024. “Advancing Treatment Efficacy: Combined Therapy of Eribulin, Anlotinib, and Camrelizumab in Advanced or Metastatic Retroperitoneal Liposarcoma.” Therapeutic Advances in Medical Oncology, September, 1–14. doi:10.1177/17588359241276968.